TGFB1 and plasma cell myeloma: TGFβ, as described above, is secreted by patient myeloma cells and BMSC34 and is also liberated from bone matrix upon resorption.57 Importantly, TGFβ is also an inhibitor of osteoblast differentiation, thus contributing to the mechanism of bone disease in myeloma patients.